Skip to content

Prevention of type 2 diabetes in HIV: a pilot study of effectiveness and acceptability

Prevention of type 2 diabetes in HIV: a pilot study of effectiveness and acceptability: a non-randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN58156277
Enrollment
162
Registered
2014-01-30
Start date
2013-12-23
Completion date
Unknown
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Diabetes Research Network, Infection

Interventions

Lifestyle advice, 6 months of individualised diet and physical activity advice

Sponsors

Guy's and St Thomas' NHS Foundation trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Part 1: 1. HIV positive adults aged 18 years 2. Are competent in English language Part 2: 1. HIV positive adults aged 18 years old 2. Stable on current antiretrovirals for last 6 months 3. Unlikely to need to change their antiretrovirals within the next 6 months 4. Have insulin resistance (fasting glucose 5.6 - 6.9 mmol/l) 5. Able to give informed consent 6. Willing and able to participate in an exercise programme 7. Able to attend monthly appointments for 6 months 8. In the opinion of the investigator will be unlikely to have any planned events within the next 6 months that would prevent adherence to a lifestyle change programme 9. Competent in English language Part 3: 1. Those exiting Part 2 after completing the 6 month intervention 2. Those who withdraw from Part 2 after the initial visit and before completing the 6 month intervention 3. Those who were eligible for Part 2, declined the intervention, but consented to interview Part 4: 1. HIV positive expert patient or patient representative, or an HIV advocate or 2. Health professional working in HIV care

Exclusion criteria

Exclusion criteria: Part 1: 1. Unable to attend for a single visit 2. Type 1 diabetes Part 2: 1. Have a clinical diagnosis of type 1 or type 2 diabetes 2. Have a fasting glucose indicative of diabetes (=7.0 mmol /l) 3. Have a random glucose indicative of diabetes (=11.1 mmol/l) 4. Are pregnant, planning for a pregnancy, or lactating 5. Are naive to antiretroviral therapy 6. Have medical problems that may interfere with patient safety 7. Have a current medical condition that makes exercise inadvisable 8. Are fitted with an artificial cardiac pacemaker device 9. Have liver impairment suggested by liver function tests (ALT) within the last year elevated =2.5 times above the upper level of the laboratory reference range 10. Have hepatitis B and/or C coinfection 11. Use medicines that might interfere with glucose homeostasis measures, e.g. corticosteroids, anabolic steroids, testosterone or diabetes medications Part 3: 1. Are unable to undertake the interview within two weeks of withdrawing/completing, as beyond this time the participant?s history may change as elements are forgotten. Part 4: 1. Are unable to attend a single focus group

Design outcomes

Primary

MeasureTime frame
Change in insulin resistance; Timepoint(s): Measured by frequently sampled liquid meal tolerance test at Day 1 and Day 180

Secondary

MeasureTime frame
1. Blood pressure; Timepoint(s): day 1 and day 180 2. Change in anthropometry; Timepoint(s): day 1 and day 180 3. Change in dietary intake; Timepoint(s): day 1 and day 180 4. Change in lipids; Timepoint(s): day 1 and day 180 5. Change in physical activity; Timepoint(s): day 1 and day 180 6. Quality of life; Timepoint(s): day 1 and day 180

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026